ClinicalTrials.gg
CompletedNCT02345213Updated Jan 8, 2019

A Post-Marketing Clinical Study of Aricept in Patients With Dementia With Lewy Bodies (DLB)

A Phase 4 interventional study of E2020 and Placebo in Dementia, Lewy Body and Lewy Body Disease, sponsored by Eisai Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 50 Years to 99 Years. Per ClinicalTrials.gov, last updated 2019-01-08.

Sponsored by Eisai Co., Ltd. · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
50 Years to 99 Years
Sex
All
01

Study summary

The purpose of this study is to confirm the efficacy of Aricept in patients with dementia with Lewy bodies (DLB).

02

Conditions studied

  • Dementia, Lewy Body
  • Lewy Body Disease

Keywords

  • DLB
  • Dementia with Lewy bodies
  • Lewy Body Disease
  • Dementia
  • E2020
  • Donepezil
  • Aricept
03

In context

Lewy Body Disease

239 studies on the registry are indexed under Lewy Body Disease; 88 are open to participants now.

This study's enrollment of 160 is above the median of 86 across 152 interventional studies indexed under Lewy Body Disease.

Browse Lewy Body Disease studies →

Lead sponsor

Eisai Co., Ltd. is the lead sponsor of 152 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients diagnosed with probable DLB according to the diagnostic criteria for DLB
  2. Patients having caregivers throughout the study who submit written consent to cooperate with this study, can routinely stay with patients at least 3 days a week (at least 4 hours a day), provide patients' information necessary for this study, assist treatment compliance, and escort the patients on required visits to study institution
  3. Clinical Dementia Rating (CDR) score is greater than or equal to 0.5
  4. (MMSE) score is greater than or equal to 10 and less than or equal to 26

Exclusion criteria

Exclusion Criteria

  1. Patients diagnosed with Parkinson's disease with dementia (PDD)
  2. Patients who have received anti-dementia drug therapy within 12 weeks before the start of the observation period
  3. Patients with a complication of serious neuropsychiatric disease(s) such as stroke, brain tumor, schizophrenia, epilepsy, normal pressure hydrocephalus, mental retardation, brain trauma with unconsciousness, or a history of brain surgery causing unrecovered deficiency
  4. Patients with severe extrapyramidal disorders (Hoehn and Yahr staging score is greater than or equal to IV)
  5. Patients whose systolic blood pressure is less than 90 mmHg or pulse rate is less than 50 beats/minute at screening test
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
160 participants (actual)

Study arms

  • Experimental
    E2020

    Treatment period: Weeks 1-2 E2020 3 mg, Weeks 3-6 E2020 5 mg, Weeks 7-12 E2020 10 mg. Extension period: Weeks 1-6 E2020 10 mg, After Week 7 up to week 60 E2020 10 mg.

    Drug: E2020

  • Placebo comparator
    Placebo

    Treatment period: Weeks 1-12 placebo Extension period: Weeks 1-2 E2020 3 mg, Weeks 3-6 E2020 5 mg, After Week 7 up to week 60 E2020 10 mg.

    Drug: Placebo

Interventions

  • DrugE2020

    E2020 tablets will be orally administered once daily after breakfast

  • DrugPlacebo

    Matching placebo tablets will be orally administered once daily after breakfast

06

What researchers measure

Primary outcomes

  1. Clinician's Interview-Based Impression of Change, Plus Caregiver Input Version (CIBIC-plus)

    CIBIC plus is a clinician's interview-based impression of change plus the caregiver's input. It is a seven-point categorical assessment scale for evaluating global clinical function, ranging from "markedly improved" to "markedly worse".

    Time frame: Up to 12 weeks

07

Study locations

1 site
  • Saitama, Japan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2015 to primary completion in May 2017, 26 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2015
First posted
Jan 26, 2015
StartActual
Mar 1, 2015
Primary completionActual
May 15, 2017
CompletionActual
Mar 26, 2018
Last update
Jan 8, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02345213
Lead sponsor
Eisai Co., Ltd.
Responsible party
Sponsor
First posted
Jan 26, 2015
Start date
Mar 1, 2015
Primary completion
May 15, 2017
Completion
Mar 26, 2018
Last update
Jan 8, 2019

Study contacts

Megumi Ohdake
study director · Drug Fostering and Evolution Coordination Department, Eisai Co., Ltd.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donepezil

Start the discussion